Expert Review of Clinical Pharmacology | 2021
Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer
Abstract
ABSTRACT Background This study aimed to quantitatively evaluate factors influencing the efficacy and safety of the docetaxel–platinum regimen to provide reliable information for optimizing chemotherapy regimens. Research design and methods A parametric survival function model was used to describe the time course of overall survival (OS) of patients with advanced non-small cell lung cancer (NSCLC) receiving a docetaxel–platinum regimen. A random-effects model in a single-arm meta-analysis was used to analyze the objective response rate and grade 3–4 adverse event rates based on various docetaxel–platinum regimens. Results The model revealed that the risk of death in East Asians was approximately 1.5-fold higher than that in non-East Asians, with a median OS of 13.7 (95% confidence interval [CI]: 12.8–14.7) months and 9.3 (95% CI: 7.7–11.1) months, respectively. No significant impact of different administration regimens on OS was found. However, when drug exposure increased, the incidence of grade 3–4 anemia or neutropenia significantly increased. Conclusions The docetaxel–platinum regimen has different efficacies in the treatment of advanced NSCLC between East Asian and non-East Asian populations. A better benefit–risk ratio can be obtained with a lower exposure regimen of docetaxel combined with platinum.